A randomized, multicenter, phase II trial comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer (Neo-peaks study)
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Letrozole; Tamoxifen; Trastuzumab emtansine
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms Neo-peaks
- 30 Jul 2021 Status changed from active, no longer recruiting to completed.
- 12 Oct 2017 A total of 206 patients were enrolled (Aug 2014-Feb 2016), according to results presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Results (n=204) comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer, were presented at the 42nd European Society for Medical Oncology Congress.